Discover and read the best of Twitter Threads about #Morepen
Most recents (4)
@dr_morepen
#API Formulations HomeHealth
Api - loratadine,Atorvastatin,Montelukast,Fexofenadine,Rosuvastatin,Sitagliptin,Olmesartan,Voglibose,Dapagliflozin,Vildagliptin etc
Formulations - antibiotics,GI,CNS,Ortho,Calcium,Respiratory,Antiallergic,Nutraceuticals
#pharma #Nifty
#API Formulations HomeHealth
Api - loratadine,Atorvastatin,Montelukast,Fexofenadine,Rosuvastatin,Sitagliptin,Olmesartan,Voglibose,Dapagliflozin,Vildagliptin etc
Formulations - antibiotics,GI,CNS,Ortho,Calcium,Respiratory,Antiallergic,Nutraceuticals
#pharma #Nifty
Devices - BP monitor,Glucometer,Pulse oximeter,Thermometer
Mcap - 1320
CMP - 29.4
P/E 19.3
BV 7.36
FV 2
ROCE 10.2
OPM 8.97
D/E 0.05
EVEBIDTA 12.2
EPS 0.75
Int coverage 40.8
Mcap - 1320
CMP - 29.4
P/E 19.3
BV 7.36
FV 2
ROCE 10.2
OPM 8.97
D/E 0.05
EVEBIDTA 12.2
EPS 0.75
Int coverage 40.8
@dr_morepen investor presentation Q2fy21
Q2 fy20/Q2fy21 in crs
Revenue 216/340,up 57%
Ebidta 17.8/35.4,up 99%
PAT 4.08/27.17 ,up 566%
EPS 0.09/0.6,up 566%
3 verticals
Bulk drugs(#API ) - antidiabetics,antihypertensive,antivirals,anticancer,neuropsychologica
#Morepen
Q2 fy20/Q2fy21 in crs
Revenue 216/340,up 57%
Ebidta 17.8/35.4,up 99%
PAT 4.08/27.17 ,up 566%
EPS 0.09/0.6,up 566%
3 verticals
Bulk drugs(#API ) - antidiabetics,antihypertensive,antivirals,anticancer,neuropsychologica
#Morepen
Respected all sir
I have observe that many times after high volume candle formed stocks price drop and that high volume candle's high is protected and break that high by another high volume candle only.
Here are some examples.
I have cover all large, mid and small cap stocks
I have observe that many times after high volume candle formed stocks price drop and that high volume candle's high is protected and break that high by another high volume candle only.
Here are some examples.
I have cover all large, mid and small cap stocks
Burnol?
Really complex APIs, formulations, branded segments, home diagnostics and whatnot. If growth in API happens, should cross all-time high. The stock corrected 30% even after the best Nos. Debt-free. repaid the debt of 100 Cr in last 5 yrs
expresspharma.in/latest-updates…
Really complex APIs, formulations, branded segments, home diagnostics and whatnot. If growth in API happens, should cross all-time high. The stock corrected 30% even after the best Nos. Debt-free. repaid the debt of 100 Cr in last 5 yrs
expresspharma.in/latest-updates…
Invested by looking at the complexity of API they make, believe me, I am a chemist.
Few silent features: 80% US market share in Loratidine API that's amazing. Other APIs doing well are Montelukast, Atorvastatin, Rosuvastatin, all complex.
Few silent features: 80% US market share in Loratidine API that's amazing. Other APIs doing well are Montelukast, Atorvastatin, Rosuvastatin, all complex.
3 Diabetic APIs under development. API Sales Revenue during the year 2020-21 grew by 14.74 percent at Rs. 473.95 crores with an impressive growth of 28 percent in Domestic and 10 percent in Exports.
High risk investment idea Morepen labs
1- High risk because corporate governance problem , payment default etc ( enter at your own risk it’s not my recommendation .
2-Ideal buying range 12-15
1- High risk because corporate governance problem , payment default etc ( enter at your own risk it’s not my recommendation .
2-Ideal buying range 12-15
3-Sales from 2014 to 19 increased from 367 Cr to 769 Cr in 2019 and loss of 3 Cr in 2014 to profit of 29 Cr in 2019
4- financial parameters presently not attractive at but going forward I hope improvement will be there (with growing business, zero debt , backward integration.
